Enlarged Prostate Resources
The following is a list of enlarged prostate resources and Web sites that you might find helpful. Also included are the primary references we used to build the RealAge Enlarged Prostate Health Assessment and related information. When you click on a link, your browser will launch a new window, and you'll be visiting a third-party site. To return to RealAge, simply close the new window.
General Information
American Urological Association Education and Research
National Kidney and Urologic Diseases Information Clearinghouse – Prostate Enlargement
Primary Articles
American Urological Association Guideline: Management of Benign Prostatic Hyperplasia. McVary, K. T. et al. American Urological Association, Revised 2010.
Benign prostatic hyperplasia: diagnosis and treatment guideline. Lee M, Sharifi R., Annals of Pharmacotherapy 1997 Apr;31(4):481-486.
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Buzelin, J. M., Fonteyne, E., Kontturi, M., Witjes, W. P., Khan, A., British Journal of Urology 1997 Oct;80(4):597-605.
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M., Waldstreicher, J., New England Journal of Medicine 1998 Feb 26;338(9):557-563.
Epidemiology and natural history of benign prostatic hyperplasia. Barry, M. J., The Urologic Clinics of North America 1990 Aug;17(3):495-507.
Finasteride for benign prostatic hyperplasia. Tacklind, J. et al., Cochrane Database Systematic Reviews 2010 Oct 6;(10):CD006015.
Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Geller, J., European Urology 1995;27(4):267-273.
Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Isaacs, J. T., Prostate (supplement) 1990;3:1-7.
Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Marberger, M. J., Urology 1998 May;51(5):677-686.
Management of symptomatic BPH in the US: who is treated and how? Bruskewitz, R., European Urology 1999;36 Suppl 3:7-13.
The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. Barry, M. J., Fowler, F. J. Jr., Bin, L., Pitts, J. C. 3rd, Harris, C. J., Mulley, A. G. Jr., Journal of Urology 1997 Jan;157(1):10-14; discussion 14-15.
Natural history of prostatism: risk factors for acute urinary retention. Jacobsen, S. J., Jacobson, D. J., Girman, C. J., Roberts, R. O., Rhodes, T., Guess, H. A., Lieber, M. M., Journal of Urology 1997 Aug;158(2):481-487.
The prevalence of prostatism: a population-based survey of urinary symptoms. Chute, C. G., Panser, L. A., Girman, C. J., Oesterling, J. E., Guess, H. A., Jacobsen, S. J., Lieber, M. M., Journal of Urology 1993 Jul;150(1):85-89.
Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Roehrborn, C. G., Siegel, R. L., Urology 1996 Sep;48(3):406-415.
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. Roehrborn, C. G., McConnell, J., Bonilla, J., Rosenblatt, S., Hudson, P. B., Malek, G. H., Schellhammer, P. F., Bruskewitz, R., Matsumoto, A. M., Harrison, L. H., Fuselier, H. A., Walsh, P., Roy, J., Andriole, G., Resnick, M., Waldstreicher, J., Journal of Urology 2000 Jan;163(1):13-20.
